BioSpace News Archive

Juvena Therapeutics today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.

Satellos Bioscience Inc. announced that Alan K. Jacobs, M.D., Chief Medical Officer, has left the Company to pursue other opportunities.

GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.

QuidelOrtho Corporation announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024.

STAAR Surgical Company and SharpeVision announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses.

S2 Genomics announced today that it has raised $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies (RCT).

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy.

Cybin Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug (“IND”) application for CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of Generalized Anxiety Disorder (“GAD”).

The International Academy of Oral Medicine and Toxicology is pleased to announce the publication of its new position paper on Human Jawbone Cavitations.

Anixa Biosciences, Inc. today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”